Table_1_[68Ga]-Pentixafor PET/CT for CXCR4-Mediated Imaging of Vestibular Schwannomas.DOCX

We have recently demonstrated CXCR4 overexpression in vestibular schwannomas (VS). This study investigated the feasibility of CXCR4-directed positron emission tomography/computed tomography (PET/CT) imaging of VS using the radiolabeled chemokine ligand [68Ga]Pentixafor.Methods: 4 patients with 6 primarily diagnosed or pre-treated/observed VS were enrolled. All subjects underwent [68Ga]Pentixafor PET/CT prior to surgical resection. Images were analyzed visually and semi-quantitatively for CXCR4 expression including calculation of tumor-to-background ratios (TBR). Immunohistochemistry served as standard of reference in three patients.Results: [68Ga]Pentixafor PET/CT was visually positive in all cases. SUVmean and SUVmax were 3.0 ± 0.3 and 3.8 ± 0.4 and TBRmean and TBRmax were 4.0 ± 1.4 and 5.0 ± 1.7, respectively. Histological analysis confirmed CXCR4 expression in tumors.Conclusion: Non-invasive imaging of CXCR4 expression using [68Ga]Pentixafor PET/CT of VS is feasible and could prove useful for in vivo assessment of CXCR4 expression.</p

Supplementary Figures 1-5 from Cytotoxic T Cells and their Activation Status are Independent Prognostic Markers in Meningiomas

Fig. S1: Workflow; Fig. S2: Representative gating strategy for TissueFAXS analysis; Fig. S3: Analysis of helper, cytotoxic and regulatory T cell infiltration and the proportion of PD-1-expressing T cells; Fig. S4: Association between the infiltration of T cells and survival; Fig. S5: Levels of tumor-infiltrating T lymphocytes (TILs) in meningiomas, separated by their localization.</p

Supplementary Figure Legends from Cytotoxic T Cells and their Activation Status are Independent Prognostic Markers in Meningiomas

Supplementary Figure Legends</p

Supplementary Tables 1-2 from Cytotoxic T Cells and their Activation Status are Independent Prognostic Markers in Meningiomas

Suppl. Table S1: Impact of cytotoxic T-cells on patient survival; Suppl. Table S2: Impact of PD-1-expressing cytotoxic T-cells on patient survival</p